Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416637 | 1.00 | PPARG (0.65) | PPARGPPARA | |
| SCHEMBL5892314 | 1.00 | PPARG (0.65) | PPARGPPARA | |
| SCHEMBL5421831 | 0.94 | PPARA (0.67) | PPARGPPARA | |
| SCHEMBL5429733 | 0.94 | PPARA (0.67) | PPARGPPARA | |
| SCHEMBL5427997 | 0.94 | PPARA (0.67) | PPARGPPARA | |
| SCHEMBL5427011 | 0.93 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL5427010 | 0.93 | PPARG (0.66) | PPARGPPARA | |
| SCHEMBL5424349 | 0.93 | PPARG (0.68) | PPARGPPARA | |
| SCHEMBL5424352 | 0.93 | PPARG (0.68) | PPARGPPARA | |
| SCHEMBL5892300 | 0.93 | PPARG (0.62) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1502590-B1 | Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes | SERVIER LAB (FR) | 2006-12-20 | — | — | EP | claimed |
| US-20070167502-A1 | Association between a heterocyclic compound and an antioxidant agent | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2007-07-19 | — | — | US | disclosed |
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167502-A1 | Association between a heterocyclic compound and an antioxidant agent | PC, LIPC, GPR119 | PPARG 47/4885PPARA 89/4885 |
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | PPARG 785/4885PPARA 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.